Synergy Pharmaceuticals, Inc Common Stock
SGYP
SGYP was delisted on the 7th of March, 2019.
150 hedge funds and large institutions have $292M invested in Synergy Pharmaceuticals, Inc Common Stock in 2017 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 53 increasing their positions, 40 reducing their positions, and 22 closing their positions.
41% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 22
33% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 40
5% more funds holding
Funds holding: 143 → 150 (+7)
33% less capital invested
Capital invested by funds: $436M → $292M (-$143M)
56% less call options, than puts
Call options by funds: $4.07M | Put options by funds: $9.27M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$29.3M |
| 2 |
State Street
Boston,
Massachusetts
|
+$18.1M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$17.4M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5M |
| 5 |
BlackRock
New York
|
+$4.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Paulson & Co
New York
|
-$49.9M |
| 2 |
O
OrbiMed
New York
|
-$39.5M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$14.6M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$9.49M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$5.86M |
SGYP Hedge Fund Activity: Q4 2017 in Review
150 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Synergy Pharmaceuticals, Inc Common Stock (SGYP) for Q4 2017, worth a combined $292M — down 33% from $436M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new SGYP positions and 22 closed out — a net gain of 9 holders — while 53 added to existing stakes and 40 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $29.3M. The largest seller was Paulson & Co, cutting an estimated $49.9M.
- 150 institutional investors held Synergy Pharmaceuticals, Inc Common Stock (SGYP) as of Q4 2017, up from 143 in Q3 2017.
- Funds reported $292M of Synergy Pharmaceuticals, Inc Common Stock stock for Q4 2017, down 33% quarter-over-quarter.
- 31 funds opened new Synergy Pharmaceuticals, Inc Common Stock positions in Q4 2017 and 22 closed out, a net change of +9 holders.
- The largest Synergy Pharmaceuticals, Inc Common Stock buyer in Q4 2017 was Susquehanna International Group, an estimated $29.3M added.
- The largest Synergy Pharmaceuticals, Inc Common Stock seller in Q4 2017 was Paulson & Co, an estimated $49.9M sold.
Based on aggregated 13F filings for Q4 2017.